Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Regorafenib in advanced solitary fibrous tumor
2015-002629-21Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in hemangiopericytoma (HPC), mesenchymal tumor and cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall tumor Response Rate (Choi criteria including MRI). Started Jan 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
hemangiopericytoma (HPC)mesenchymal tumorcancer
Beyond the preview
Go deeper on 2015-002629-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002629-21.